

1fw

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/817,570
Filing Date	April 1, 2004
First Named Inventor	Charles David Claude
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket Number	5063.00384

Total Number of Pages in This Submission (excluding references) 17

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Deposit Account 07-1850 Authorization	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Drawing(s) In/Formal ___ Sheets with Submission of Drawings Transmittal	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Petition for Extension of Time (___ months) (in duplicate)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Information Disclosure Statement (in duplicate) with Form PTO-1449 (12 pgs) citing 334 References	<input type="checkbox"/> Terminal Disclaimer	78 References
<input type="checkbox"/> Express Mail Label No.	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Brian S. Boyer, Ph.D., Reg. No. 52,643
Signature	
Date	June 9, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: June 9, 2005

Typed or printed name	Vera Breder		
Signature		Date	June 9, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

Examiner: Unassigned

Charles David Claude

Serial No. 10/817,570

Art Unit: 1615

Filed: April 1, 2004

Title: CONTROLLED MORPHOLOGIES IN POLYMER DRUG FOR
RELEASE OF DRUGS FROM POLYMER FILMS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. Since this patent application was filed after June 30, 2003, Applicant has not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Supplemental Information Disclosure Statement is not to be

construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Supplemental Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: June 9, 2005

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,


Brian S. Boyer, Ph.D.
Attorney for Applicant
Reg. No. 52,643

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No. 50623.384		Application No. 10/817,570	
US Patent and Trademark Office				Applicant Charles David Claude			
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Filing Date April 1, 2004		Group Art Unit 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,386,454	10/9/45	Frosch et al.			
	A2	3,773,737	11/20/73	Goodman et al.			
	A3	3,849,514	11/19/74	Gray, Jr. et al.			
	A4	4,226,243	10/7/80	Shalaby et al.			
	A5	4,329,383	5/11/82	Joh			
	A6	4,343,931	8/10/82	Barrows			
	A7	4,529,792	7/16/85	Barrows			
	A8	4,611,051	9/9/86	Hayes et al.			
	A9	4,656,242	4/7/87	Swan et al.			
	A10	4,733,665	3/29/88	Palmaz			
	A11	4,800,882	1/31/89	Gianturco			
	A12	4,886,062	12/12/89	Wiktor			
	A13	4,931,287	6/5/90	Bae et al.			
	A14	4,941,870	7/17/90	Okada et al.			
	A15	5,019,096	5/28/91	Fox, Jr. et al.			
	A16	5,100,992	3/31/92	Cohn et al.			
	A17	5,112,457	5/12/92	Marchant			
	A18	5,133,742	7/28/92	Pinchuk			
	A19	5,163,952	11/17/92	Froix			
	A20	5,165,919	11/24/92	Sasaki et al.			
	A21	5,219,980	6/15/93	Swidler			
	A22	5,258,020	11/2/93	Froix			
	A23	5,272,012	12/21/93	Opolski			
	A24	5,306,786	4/26/94	Moens et al.			
	A25	5,380,299	1/10/95	Fearnot et al.			

A26	5,417,981	5/23/95	Endo et al.			
A27	5,447,724	9/5/95	Helmus et al.			
A28	5,455,040	10/3/95	Marchant			
A29	5,464,650	11/7/95	Berg et al.			
A30	5,485,496	1/16/96	Lee et al.			
A31	5,516,881	5/14/96	Lee et al.			
A32	5,569,463	10/29/96	Helmus et al.			
A33	5,584,877	12/17/96	Miyake et al.			
A34	5,607,467	3/4/97	Froix			
A35	5,609,629	3/11/97	Fearnot et al.			
A36	5,610,241	3/11/97	Lee et al.			
A37	5,616,338	4/1/97	Fox, Jr. et al.			
A38	5,624,411	4/29/97	Tuch			
A39	5,644,020	7/1/97	Timmermann et al.			
A40	5,649,977	7/22/97	Campbell			
A41	5,674,242	10/7/97	Phan et al.			
A42	5,679,400	10/21/97	Tuch			
A43	5,702,754	12/30/97	Zhong			
A44	5,711,958	1/27/98	Cohn et al.			
A45	5,721,131	2/24/98	Rudolph et al.			
A46	5,723,219	3/3/98	Kolluri et al.			
A47	5,735,897	4/7/98	Buirge			
A48	5,759,205	6/2/98	Valentini			
A49	5,776,184	7/7/98	Tuch			
A50	5,783,657	7/21/98	Pavlin et al.			
A51	5,788,979	8/4/98	Alt et al.			
A52	5,820,917	10/13/98	Tuch			
A53	5,824,048	10/20/98	Tuch			
A54	5,837,008	11/17/98	Berg et al.			
A55	5,849,859	12/15/98	Acemoglu			
A56	5,854,376	12/29/98	Higashi			
A57	5,858,746	1/12/99	Hubbell et al.			

A58	5,869,127	2/9/99	Zhong			
A59	5,876,433	3/2/99	Lunn			
A60	5,877,224	3/2/99	Brocchini et al.			
A61	5,879,713	3/9/99	Roth et al.			
A62	5,902,875	5/11/99	Roby et al.			
A63	5,905,168	5/18/99	Dos Santos et al.			
A64	5,910,564	6/8/99	Gruning et al.			
A65	5,914,387	6/22/99	Roby et al.			
A66	5,919,893	7/6/99	Roby et al.			
A67	5,932,299	8/3/99	Katoot			
A68	5,958,385	9/28/99	Tondeur et al.			
A69	5,962,138	10/5/99	Kolluri et al.			
A70	5,997,517	12/7/99	Whitbourne			
A71	6,011,125	1/4/00	Lohmeijer et al.			
A72	6,033,582	3/7/00	Lee et al.			
A73	6,034,204	3/7/00	Mohr et al.			
A74	6,042,875	3/28/00	Ding et al.			
A75	6,051,576	4/18/00	Ashton et al.			
A76	6,051,648	4/18/00	Rhee et al.			
A77	6,054,553	4/25/00	Groth et al.			
A78	6,056,993	5/2/00	Leidner et al.			
A79	6,060,451	5/9/00	DiMaio et al.			
A80	6,080,488	6/27/00	Hostettler et al.			
A81	6,099,562	8/8/00	Ding et al.			
A82	6,110,188	8/29/00	Narciso, Jr.			
A83	6,110,483	8/29/00	Whitbourne et al.			
A84	6,113,629	9/5/00	Ken			
A85	6,120,491	9/19/00	Kohn et al.			
A86	6,120,536	9/19/00	Ding et al.			
A87	6,120,788	9/19/00	Barrows			
A88	6,120,904	9/19/00	Hostettler et al.			
A89	6,121,027	9/19/00	Clapper et al.			
A90	6,129,761	10/10/00	Hubbell			

	A91	6,136,333	10/24/00	Cohn et al.			
	A92	6,143,354	11/7/00	Koulik et al.			
	A93	6,159,978	12/12/00	Myers et al.			
	A94	6,172,167	1/9/01	Stapert et al.			
	A95	6,177,523	1/23/01	Reich et al.			
	A96	6,180,632	1/30/01	Myers et al.			
	A97	6,203,551	3/20/01	Wu			
	A98	6,211,249	4/3/01	Cohn et al.			
	A99	6,214,901	4/10/01	Chudzik et al.			
	A100	6,231,600	5/15/01	Zhong			
	A101	6,240,616	6/5/01	Yan			
	A102	6,245,753	6/12/01	Byun et al.			
	A103	6,245,760	6/12/01	He et al.			
	A104	6,248,129	6/19/01	Froix			
	A105	6,251,136	6/26/01	Guruwaiya et al.			
	A106	6,254,632	7/3/01	Wu et al.			
	A107	6,258,121	7/10/01	Yang et al.			
	A108	6,258,371	7/10/01	Koulik et al.			
	A109	6,262,034	7/17/01	Mathiowitz et al.			
	A110	6,270,788	8/7/01	Koulik et al.			
	A111	6,277,449	8/21/01	Kolluri et al.			
	A112	6,283,947	9/4/01	Mirzaee			
	A113	6,283,949	9/4/01	Roorda			
	A114	6,284,305	9/4/01	Ding et al.			
	A115	6,287,628	9/11/01	Hossainy et al.			
	A116	6,299,604	10/9/01	Ragheb et al.			
	A117	6,306,176	10/23/01	Whitbourne			
	A118	6,331,313	12/18/01	Wong et al.			
	A119	6,335,029	1/1/02	Kamath et al.			
	A120	6,344,035	2/5/02	Chudzik et al.			
	A121	6,346,110	2/12/02	Wu			

	A122	6,358,556	3/19/02	Ding et al.			
	A123	6,379,381	4/30/02	Hossainy et al.			
	A124	6,387,379	5/14/02	Goldberg et al.			
	A125	6,395,326	5/28/02	Castro et al.			
	A126	6,419,692	7/16/02	Yang et al.			
	A127	6,451,373	9/17/02	Hossainy et al.			
	A128	6,482,834	11/19/02	Spada et al.			
	A129	6,494,862	12/17/02	Ray et al.			
	A130	6,503,538	1/7/03	Chu et al.			
	A131	6,503,556	1/7/03	Harish et al.			
	A132	6,503,954	1/7/03	Bhat et al.			
	A133	6,506,437	1/14/03	Harish et al.			
	A134	6,524,347	2/25/03	Myers et al.			
	A135	6,527,801	3/4/03	Dutta			
	A136	6,527,863	3/4/03	Pacetti et al.			
	A137	6,528,526	3/4/03	Myers et al.			
	A138	6,530,950	3/11/03	Alvarado et al.			
	A139	6,530,951	3/11/03	Bates et al.			
	A140	6,540,776	4/1/03	Sanders Millare et al.			
	A141	6,544,223	4/8/03	Kokish			
	A142	6,544,543	4/8/03	Mandrusov et al.			
	A143	6,544,582	4/8/03	Yoe			
	A144	6,555,157	4/29/03	Hossainy			
	A145	6,558,733	5/6/03	Hossainy et al.			
	A146	6,565,659	5/20/03	Pacetti et al.			
	A147	6,572,644	6/3/03	Moein			
	A148	6,585,755	7/1/03	Jackson et al.			
	A149	6,585,765	7/1/03	Hossainy et al.			
	A150	6,585,926	7/1/03	Mirzaee			
	A151	6,605,154	8/12/03	Villareal			

	A152	6,616,765	9/9/03	Hossaony et al.			
	A153	6,623,448	9/23/03	Slater			
	A154	6,625,486	9/23/03	Lundkvist et al.			
	A155	6,645,135	11/11/03	Bhat			
	A156	6,645,195	11/11/03	Bhat et al.			
	A157	6,656,216	12/2/03	Hossainy et al.			
	A158	6,656,506	12/2/03	Wu et al.			
	A159	6,660,034	12/9/03	Mandrusov et al.			
	A160	6,663,662	12/16/03	Pacetti et al.			
	A161	6,663,880	12/16/03	Roorda et al.			
	A162	6,666,880	12/23/03	Chiu et al.			
	A163	6,673,154	1/6/04	Pacetti et al.			
	A164	6,673,385	1/6/04	Ding et al.			
	A165	6,689,099	2/10/04	Mirzaee			
	A166	6,695,920	2/24/04	Pacetti et al.			
	A167	6,706,013	3/16/04	Bhat et al.			
	A168	6,709,514	3/23/04	Hossainy			
	A169	6,712,845	3/30/04	Hossainy			
	A170	6,713,119	3/30/04	Hossainy et al.			
	A171	6,716,444	4/6/04	Castro et al.			
	A172	6,723,120	4/20/04	Yan			
	A173	6,733,768	5/11/04	Hossainy et al.			
	A174	6,740,040	5/25/04	Mandrusov et al.			
	A175	6,743,462	6/1/04	Pacetti			
	A176	6,749,626	6/15/04	Bhat et al.			
	A177	6,753,071	6/22/04	Pacetti et al.			
	A178	6,758,859	7/6/04	Dang et al.			
	A179	6,759,054	7/6/04	Chen et al.			

	A180	6,764,505	7/20/04	Hossainy et al.			
U.S. PATENT APPLICATION PUBLICATION DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A181	2001/0007083	7/5/01	Roorda			12/21/00
	A182	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A183	2001/0018469	8/30/01	Chen et al.			12/28/00
	A184	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A185	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A186	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A187	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
	A188	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A189	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A190	2002/0007214	1/17/02	Falotico			5/7/01
	A191	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A192	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A193	2002/0016625	2/7/02	Falotico et al.			5/7/01
	A194	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A195	2002/0032434	3/14/02	Chudzik et al.			11/21/01
	A196	2002/0051730	5/2/02	Bodnar et al.			9/28/01
	A197	2002/0071822	6/13/02	Uhrich			7/27/01
	A198	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A199	2002/0082679	6/27/02	Sirhan et al.			11/1/01
	A200	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A201	2002/0091433	7/11/02	Ding et al.			12/17/01
	A202	2002/0094440	7/18/02	Llanos et al.			9/25/01
	A203	2002/0111590	8/15/02	Davila et al.			9/25/01
	A204	2002/0120326	8/29/02	Michal			12/22/00
	A205	2002/0123801	9/5/02	Pacetti et al.			12/28/00
	A206	2002/0142039	10/3/02	Claude			3/30/01
	A207	2002/0155212	10/24/02	Hossainy			4/24/01
	A208	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A209	2002/0176849	11/28/02	Slepian			2/8/02

	A210	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A211	2002/0188037	12/12/02	Chudzik et al.			6/18/02
	A212	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A213	2003/0004141	1/2/03	Brown			3/8/02
	A214	2003/0028243	2/6/03	Bates et al.			8/14/02
	A215	2003/0028244	2/6/03	Bates et al.			8/14/02
	A216	2003/0031780	2/13/03	Chudzik et al.			10/10/02
	A217	2003/0032767	2/13/03	Tada et al.			2/5/01
	A218	2003/0036794	2/20/03	Ragheb et al.			8/19/02
	A219	2003/0039689	2/27/03	Chen et al.			4/26/02
	A220	2003/0040712	2/27/03	Ray et al.			10/10/02
	A221	2003/0040790	2/27/03	Furst			7/31/02
	A222	2003/0059520	3/27/03	Chen et al.			9/27/01
	A223	2003/0060877	3/27/03	Falotico et al.			4/15/02
	A224	2003/0065377	4/3/03	Davila et al.			4/30/02
	A225	2003/0072868	4/17/03	Harish et al.			11/25/02
	A226	2003/0073961	4/17/03	Happ			9/28/01
	A227	2003/0083646	5/1/03	Sirhan et al.			12/14/01
	A228	2003/0083739	5/1/03	Cafferata			9/24/02
	A229	2003/0097088	5/22/03	Pacetti			11/12/01
	A230	2003/0097173	5/22/03	Dutta			1/10/03
	A231	2003/0099712	5/29/03	Jayaraman			11/26/01
	A232	2003/0105518	6/5/03	Dutta			1/10/03
	A233	2003/0113439	6/19/03	Pacetti et al.			11/18/02
	A234	2003/0150380	8/14/03	Yoe			2/19/03
	A235	2003/0157241	8/21/03	Hossainy et al.			3/5/03
	A236	2003/0158517	8/21/03	Kokish			2/11/03
	A237	2003/0190406	10/9/03	Hossainy et al.			4/10/03
	A238	2003/0207020	11/6/03	Villareal			4/22/03
	A239	2003/0211230	11/13/03	Pacetti et al.			4/7/03
	A240	2004/0018296	1/29/04	Castro et al.			6/23/03
	A241	2004/0029952	2/12/04	Chen et al.			8/1/03
	A242	2004/0047978	3/11/04	Hossainy et al.			8/12/03

	A243	2004/0047980	3/11/04	Pacetti et al.			9/8/03
	A244	2004/0052858	3/18/04	Wu et al.			9/15/03
	A245	2004/0052859	3/18/04	Wu et al.			9/15/03
	A246	2004/0054104	3/18/04	Pacetti			9/5/02
	A247	2004/0060508	4/1/04	Pacetti et al.			9/12/03
	A248	2004/0062853	4/1/04	Pacetti et al.			10/2/03
	A249	2004/0063805	4/1/04	Pacetti et al.			9/19/02
	A250	2004/0071861	4/15/04	Mandrusov et al.			10/2/03
	A251	2004/0072922	4/15/04	Hossainy et al.			10/9/02
	A252	2004/0073298	4/15/04	Hossainy			10/8/03
	A253	2004/0086542	5/6/04	Hossainy et al.			12/16/02
	A254	2004/0086550	5/6/04	Roorda et al.			10/24/03
	A255	2004/0096504	5/20/04	Michal			11/12/03
	A256	2004/0098117	5/20/04	Hossainy et al.			9/22/03

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	SU 872531	10/15/81	SU (English Abstract)				
	B2	SU 876663	10/30/81	SU (English Abstract)				
	B3	SU 905228	2/15/82	SU (English Abstract)				
	B4	SU 790725	2/9/83	SU (English Abstract)				
	B5	SU 1016314	5/7/83	SU (English Abstract)				
	B6	SU 811750	9/23/83	SU (English Abstract)				
	B7	SU 1293518	2/28/87	SU (English Abstract)				
	B8	EP 0 301 856	2/1/89	SU (English Abstract)				
	B9	EP 0 396 429	11/7/90	SU (English Abstract)				
	B10	EP 0 514 406	11/25/92	EPO				
	B11	DE 42 24 401	1/27/94	Germany			X	
	B12	WO 94/09760	5/11/94	PCT				
	B13	EP 0 604 022	6/29/94	EPO				
	B14	EP 0 623 354	11/9/94	EPO				
	B15	WO 95/10989	4/27/95	PCT				
	B16	WO 95/24929	9/21/95	PCT				
	B17	EP 0 701 802	3/20/96	EPO				

	B18	EP 0 716 836	6/19/96	EPO				
	B19	WO 96/40174	12/19/96	PCT				
	B20	WO 97/10011	3/20/97	PCT				
	B21	EP 0 809 999	12/3/97	EPO				
	B22	WO 97/46590	12/11/97	PCT				
	B23	WO 98/08463	3/5/98	PCT				
	B24	EP 0 832 655	4/1/98	EPO				
	B25	WO 98/17331	4/30/98	PCT				
	B26	EP 0 850 651	7/1/98	EPO				
	B27	WO 98/32398	7/30/98	PCT				
	B28	WO 98/36784	8/27/98	PCT				
	B29	EP 0 879 595	11/25/98	EPO				
	B30	WO 99/01118	1/14/99	PCT				
	B31	EP 0 910 584	4/28/99	EPO				
	B32	EP 0 923 953	6/23/99	EPO				
	B33	WO 99/38546	8/5/99	PCT				
	B34	EP 0 953 320	11/3/99	EPO				
	B35	WO 00/02599	1/20/00	PCT				
	B36	EP 0 982 041	3/1/00	EPO				
	B37	WO 00/18446	4/6/00	PCT				
	B38	EP 1 023 879	8/2/00	EPO				
	B39	WO 01/15751	3/8/01	PCT				
	B40	WO 01/49338	7/12/01	PCT				
	B41	2001-190687	7/17/01	Japan (English Abstract)				
	B42	WO 01/51027	7/19/01	PCT				
	B43	WO 02/03890	1/17/02	PCT				
	B44	EP 1 192 957	4/3/02	EPO				
	B45	WO 02/26162	4/4/02	PCT				
	B46	WO 02/34311	5/2/02	PCT				
	B47	WO 02/056790	7/25/02	PCT				
	B48	WO 02/058753	8/1/02	PCT				
	B49	WO 02/102283	12/27/02	PCT				

	B50	WO 03/000308	1/3/03	PCT				
	B51	EP 1 273 314	1/8/03	EPO				
	B52	WO 03/022323	3/20/03	PCT				
	B53	WO 03/028780	4/10/03	PCT				
	B54	WO 03/037223	5/8/03	PCT				
	B55	WO 03/039612	5/15/03	PCT				
	B56	WO 03/080147	10/2/03	PCT				
	B57	WO 03/082368	10/9/03	PCT				
	B58	WO 04/000383	12/31/03	PCT				
	B59	WO 04/009145	1/29/04	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).						
	C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753 , printed 8/25/03 (2 pages).						
	C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent</i> (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						
	C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752 , printed 8/25/03 (2 pages).						
	C5	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).						
	C6	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).						
	C7	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).						
	C8	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).						
	C9	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).						
	C10	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).						
	C11	Huang et al., <i>Biodegradable Polymers Derived from Aminoacids</i> , Macromol. Symp. 144, 7-32 (1999).						
	C12	Katsarava et al., <i>Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarboxylic Acids</i> , Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).						
	C13	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).						
	C14	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).						
	C15	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).						

	C16	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
	C17	Saotome, et al., <i>Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid</i> , Chemistry Letters, pp. 21-24, (1991).
	C18	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
	C19	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
EXAMINER		DATE CONSIDERED
<p>EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.</p> <p>Include copy of this form with next communication to applicant.</p>		